Internal Medicine, Hematology & Oncology · Hialeah, FL
NPI
1487645149
Since 2005
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
777 E 25th St Ste 118
Hialeah, FL, 33013
Phone (305) 693-1988
Groups this clinician bills Medicare through
Medicare paid, 2024
$283K
39,673 services
Medicare patients, 2024
474
Average age 78
Drug cost, 2024
$13.1M
2,146 prescriptions
Company payments, 2025
$4,550
From 35 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Luis G Rangel was code J1756 (injection, iron sucrose, 1 mg), 13,300 times for 21 patients. In total Luis G Rangel billed 39,673 services in 41 codes, and Medicare paid $283K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-01-23.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1756 Injection, iron sucrose, 1 mg | Office | 13,300 | 21 | $0.17 | $2,254 |
| 99232 Hospital E&M - Subsequent | Facility | 1,689 | 291 | $67.16 | $113K |
| J2916 Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | Office | 640 | 13 | $1.66 | $1,064 |
| 99222 Hospital E&M - Initial | Facility | 325 | 288 | $111.99 | $36K |
| 99213 Office E&M - Established | Office | 211 | 118 | $72.91 | $15K |
| 99214 Office E&M - Established | Office | 137 | 87 | $105.32 | $14K |
| 96365 Intravenous Infusion, Hydration | Office | 137 | 32 | $49.64 | $6,800 |
| 99231 Hospital E&M - Subsequent | Facility | 100 | 30 | $42.84 | $4,284 |
| 96372 Injection Administration | Office | 94 | 21 | $10.69 | $1,005 |
| 99204 Office E&M - New | Office | 31 | 31 | $137.49 | $4,262 |
By year: 2022 $291K for 44,191 services; 2023 $279K for 31,151 services; 2024 $283K for 39,673 services.
Medicare prescription drug claims, 2024
In 2024, the drug Luis G Rangel prescribed most often to Medicare patients was Abiraterone Acetate, with 213 prescriptions and refills. In total Luis G Rangel wrote 2,146 Medicare prescriptions that cost $13.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Abiraterone Acetate Generic | 213 | 213 | 40 | $569K |
| Ondansetron Hcl Generic | 192 | 192 | 97 | $32K |
| Prochlorperazine Maleate Generic | 118 | 118 | 64 | $1,559 |
| Ondansetron Hcl Ondansetron Hcl/Pf | 104 | 104 | 19 | $669 |
| Ibrance Palbociclib | 77 | 77 | Under 11 | $1.2M |
| Calquence Acalabrutinib Maleate | 77 | 77 | Under 11 | $1.2M |
| Anastrozole Generic | 72 | 97 | 23 | $694 |
| Bosulif Bosutinib | 53 | 55 | Under 11 | $825K |
| Diphenhydramine Hcl Generic | 52 | 54 | 14 | $117 |
| Famotidine Famotidine/Pf | 50 | 50 | 13 | $87.96 |
| Dexamethasone Sodium Phosphate Generic | 47 | 47 | 12 | $120 |
| Eligard Leuprolide Acetate | 44 | 123 | 15 | $62K |
| Nubeqa Darolutamide | 43 | 43 | Under 11 | $585K |
| Imbruvica Ibrutinib | 42 | 42 | Under 11 | $697K |
| Venclexta Venetoclax | 41 | 41 | Under 11 | $570K |
Brand drugs: 928 claims; generic drugs: 1,218 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Luis G Rangel $4,550 ($4,550 in general payments such as food, travel and fees) from 35 companies. The largest payer was Novartis Pharmaceuticals Corporation with $522.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 12 | $522 |
| AstraZeneca Pharmaceuticals LP AZN | 19 | $504 |
| Genzyme Corporation SNY | 14 | $453 |
| Janssen Biotech, Inc. JNJ | 14 | $413 |
| Celgene Corporation BMY | 15 | $330 |
| Pfizer Inc. PFE | 14 | $315 |
| Daiichi Sankyo Inc. 4568.T | 10 | $238 |
| Merck Sharp & Dohme LLC MRK | 7 | $160 |
| GlaxoSmithKline, LLC. GSK | 6 | $147 |
| Sumitomo Pharma America, Inc. 4506.T | 6 | $145 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.